DNA damage response regulator ATR licenses PINK1-mediated mitophagy
Nucleic Acids Research · 27.02.2025 · 53 (5)
DOI: 10.1093/nar/gkaf178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 19.03.2025. Verfasst von Christian Marx und 15 weiteren Autor:innen. Beteiligte Einrichtung: L eibniz Institute on Aging-Fritz Lipmann Institute (FLI), Beutenbergstr. 11, 07745 Jena, Germany. Hauptthemen laut MEDLINE: Mitophagy, Ataxia Telangiectasia Mutated Proteins, Protein Kinases, DNA Damage. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German-Israeli Foundation for Scientific Research and Development, Deutsche Forschungsgemeinschaft, NIEHS NIH HHS.
Abstract (Originalsprache)
Defective DNA damage response (DDR) and mitochondrial dysfunction are a major etiology of tissue impairment and aging. Mitochondrial autophagy (mitophagy) is a mitochondrial quality control (MQC) mechanism to selectively eliminate dysfunctional mitochondria. ATR (ataxia-telangiectasia and Rad3-related) is a key DDR regulator playing a pivotal role in DNA replication stress response and genomic stability. Paradoxically, the human Seckel syndrome caused by ATR mutations exhibits premature aging and neuropathies, suggesting a role of ATR in nonreplicating tissues. Here, we report a previously unknown yet direct role of ATR at mitochondria. We find that ATR and PINK1 (PTEN-induced kinase 1) dock at the mitochondrial translocase TOM/TIM complex, where ATR interacts directly with and thereby stabilizes PINK1. ATR deletion silences mitophagy initiation thereby altering oxidative phosphorylation functionality resulting in reactive oxygen species overproduction that attack cytosolic macromolecules, in both cells and brain tissues, prior to nuclear DNA. This study discloses ATR as an integrated component of the PINK1-mediated MQC program to ensure mitochondrial fitness. Together with its DDR function, ATR safeguards mitochondrial and genomic integrity under physiological and genotoxic conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- L eibniz Institute on Aging-Fritz Lipmann Institute (FLI), Beutenbergstr. 11, 07745 Jena, Germany.
- Center for Pandemic Vaccines and Therapeutics (ZEPAI), Paul Ehrlich Institute (PEI), Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany.
- Faculty of Basic Medicine, Shenzhen University Medical School, 518055 Shenzhen, China.
- IFOM, the FIRC Institute of Molecular Oncology, 20139 Milan, Italy.
- Electron Microscopy Center, Jena University Hospital, Ziegelmühlenweg 1, 07743 Jena, Germany.
- Perelman School of Medicine, University of Pennsylvania, Philadelphia 19104, United States.
ORCID-Profile: Philipp Koch, Martin Westermann, Christopher Bruhn, Xingzhi Xu, Zhao-Qi Wang
Förderung
- German-Israeli Foundation for Scientific Research and Development
- Deutsche Forschungsgemeinschaft
- NIEHS NIH HHS
- Leibniz Association
- Shandong University
Zitieren
APA
Marx, C., Qing, X., Gong, Y., Kirkpatrick, J., Siniuk, K., Beznoussenko, G. V., Kidiyoor, G. R., Kirtay, M., Buder, K., Koch, P., Westermann, M., Bruhn, C., Brown, E. J., Xu, X., Foiani, M., & Wang, Z. Q. (2025). DNA damage response regulator ATR licenses PINK1-mediated mitophagy. Nucleic Acids Research, 53(5). https://doi.org/10.1093/nar/gkaf178
Vancouver
Marx C, Qing X, Gong Y, Kirkpatrick J, Siniuk K, Beznoussenko GV, et al. DNA damage response regulator ATR licenses PINK1-mediated mitophagy. Nucleic Acids Research. 2025;53(5). doi:10.1093/nar/gkaf178
BibTeX
@article{Marx2025,
author = {Marx, Christian and Qing, Xiaobing and Gong, Yamin and Kirkpatrick, Joanna and Siniuk, Kanstantsin and Beznoussenko, Galina V and Kidiyoor, Gururaj Rao and Kirtay, Murat and Buder, Katrin and Koch, Philipp and Westermann, Martin and Bruhn, Christopher and Brown, Eric J and Xu, Xingzhi and Foiani, Marco and Wang, Zhao-Qi},
title = {DNA damage response regulator ATR licenses PINK1-mediated mitophagy},
journal = {Nucleic Acids Research},
year = {2025},
volume = {53},
number = {5},
doi = {10.1093/nar/gkaf178}
}
EUVIMED